<DOC>
	<DOCNO>NCT02241135</DOCNO>
	<brief_summary>The purpose trial ass safety immunogenicity investigational RNActive® rabies vaccine ( CV7201 ) healthy adult .</brief_summary>
	<brief_title>RNActive® Rabies Vaccine ( CV7201 ) Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female volunteer age 18 40 year inclusive 2 . Compliant protocol procedure available clinical followup last planned visit ( V9 ) 3 . Physical examination laboratory result without clinically significant finding 4 . Body Mass Index ( BMI ) ≥ 18.0 ≤ 32.0 kg/m2 5 . Females : Negative human chorionic gonadotropin ( HCG ) pregnancy test ( serum ) woman presume reproductive potential day enrolment 6 . Females childbearing potential must use acceptable method birth control trial Followup period ( 6 week first administration test vaccine duration trial i.e. , last planned visit ( V9 ) ) . The following method birth control acceptable use consistently correctly : establish use oral , injected implant hormonal method contraception ; intrauterine device ( IUDs ) intrauterine system ( IUSs ) exception steel copper wire ; barrier method contraception ( condom occlusive cap [ diaphragm cervical/vault cap ] spermicidal foam/gel/film/cream/suppository ) ; true abstinence ( periodic abstinence [ e.g. , calendar , ovulation , symptothermal postovulation method ] withdrawal acceptable ) . 7 . Males must use reliable form contraception ( barrier method spermicidal agent true abstinence ) must refrain sperm donation trial Followup period i.e. , last planned visit ( V9 ) . 1 . Use investigational nonregistered product ( drug vaccine ) trial vaccine within 4 week precede administration trial vaccine , plan use trial period 2 . Subject receive licensed vaccine within 4 week prior administration trial vaccine 3 . Subject receive investigational licensed rabies vaccine previously 4 . Intending travel regions/countries rabies vaccination recommend high risk infection exist accord travel recommendation German Society Tropical Medicine International Health ( DTG ) trial V9 ( Day 91/120 ) Followup 5 . Any treatment immunosuppressant immunemodifying drug within 6 month prior administration trial vaccine . The use inhale nasal steroid , well topical steroid outside vaccination area , permit 6 . Any medically diagnose suspect immunodeficient condition base medical history physical examination 7 . History autoimmune disease 8 . Administration immunoglobulin ( Igs ) and/or blood product within 3 month precede administration trial vaccine 9 . Subject take chloroquine malaria treatment prophylaxis 10 . Acute disease time enrolment . Acute disease define presence moderate severe illness fever ≥ 38 °C measure orally 11 . Presence evidence significant acute chronic , uncontrolled medical psychiatric illness ( subject uncomplicated chronic diagnosis stable treat ≥ 3 month e.g. , mild hypertension wellcontrolled medication , may enrol provided condition therapy know associate immunocompromised state autoimmune disease 12 . Major congenital defect 13 . Known allergy component trial product i.e. , protamine . This include subject allergy fish protein , diabetic allergy protaminecontaining insulin , postvasectomy male 14 . Known type I allergy beta lactam antibiotic 15 . Evidence current alcohol drug abuse 16 . History neurological disorder seizure , exception febrile seizures childhood 17 . Seropositivity human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) ( except subject previously vaccinate HBV ) hepatitis C virus ( HCV ) 18 . Foreseeable noncompliance protocol judge Investigator 19 . For female : Pregnancy lactation 20 . History lifethreatening anaphylactic reaction . 21 . Subjects impaired coagulation IM injection contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rav G protein</keyword>
	<keyword>rabies</keyword>
	<keyword>VNT</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>PrEP vaccination</keyword>
	<keyword>mRNA</keyword>
	<keyword>CV7201</keyword>
</DOC>